Novel therapeutic approaches to cryoglobulinemia: Imatinib, infliximab, bortezomib, and beyond

HCV Infection and Cryoglobulinemia

Volumn 9788847017054, Issue , 2012, Pages 349-355

  Talamo, Giampaolo ^a   Zangari, Maurizio ^b  

^a PENN STATE CANCER INSTITUTE   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84864934152     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-88-470-1705-4_45     Document Type: Chapter

References (50)

1. Dammacco F, Sansonno D, Piccoli C et al (2001) The cryoglobulins: an overview. Eur J Clin Invest 31:628-638
2. Dammacco F, Sansonno D (1997) Mixed cryoglobulinemia as a model of systemic vasculitis. Clin Rev Allergy Immunol 15:97-119
3. Agnello V (1997) The etiology and pathophysiology of mixed cryoglobulinemia secondary to hepatitis C virus infection. Springer Semin Immunopathol 19:111-129
4. Brouet JC, Clauvel JP, Danon F et al (1974) Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med 57:775-788
5. Golde D, Epstein W (1968) Mixed cryoglobulins and glomerulonephritis. Ann Intern Med 69:1221-1227
6. Ristow SC, Griner PF, Abraham GN et al (1976) Reversal of systemic manifestations of cryoglobulinemia. Treatment with melphalan and prednisone. Arch Intern Med 136:467-470
7. Barnett EV, Bluestone R, Cracchiolo A 3rd et al (1970) Cryoglobulinemia and disease. Ann Intern Med 73:95-107
8. Mathison DA, Condemi JJ, Leddy JP et al (1971) Purpura, arthralgia, and IgM-IgM cryoglobulinemia with rheumatoid factor activity. Response to cyclophosphamide and splenectomy. Ann Intern Med 74:383-390
9. Frankel AH, Singer DR, Winearls CG et al (1992) Type II essential mixed cryoglobulinaemia: presentation, treatment and outcome in 13 patients. Q J Med 82:101-124
10. Ramos-Casals M, Brito-Zeron P, Munoz S et al (2008) A systematic review of the off-label use of biological therapies in systemic autoimmune diseases. Medicine (Baltimore) 87:345-364
11. Lamprecht P, Lerin-Lozano C, Merz H et al (2003) Rituximab induces remission in refractory HCV associated cryoglobulinaemic vasculitis. Ann Rheum Dis 62:1230-1233
12. Cacoub P, Delluc A, Saadoun D et al (2008) Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand? Ann Rheum Dis 67:283-287
13. Zaja F, De Vita S, Mazzaro C et al (2003) Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 101:3827-3834
14. Sansonno D, De Re V, Lauletta G et al (2003) Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 101:3818-3826
15. Valesini G, Iannuccelli C, Marocchi E et al (2007) Biological and clinical effects of anti-TNFalpha treatment. Autoimmun Rev 7:35-41
16. Kaplanski G, Marin V, Maisonobe T et al (2002) Increased soluble p55 and p75 tumour necrosis factor-alpha receptors in patients with hepatitis C-associated mixed cryoglobulinaemia. Clin Exp Immunol 127:123-130
17. Booth A, Harper L, Hammad T et al (2004) Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 15:717-721
18. Bartolucci P, Ramanoelina J, Cohen P et al (2002) Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford) 41:1126-1132
19. Josselin L, Mahr A, Cohen P et al (2008) Infliximab efficacy and safety against refractory systemic necrotising vasculitides: long-term follow-up of 15 patients. Ann Rheum Dis 67:1343-1346
20. Lamprecht P, Voswinkel J, Lilienthal T et al (2002) Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology (Oxford) 41:1303-1307
21. Mukhtyar C, Hellmich B, Jayne D et al (2006) Remission in antineutrophil cytoplasmic antibody-associated systemic vasculitis. Clin Exp Rheumatol 24:S-93-S-98
22. Chandesris MO, Gayet S, Schleinitz N et al (2004) Infliximab in the treatment of refractory vasculitis secondary to hepatitis C-associated mixed cryoglobulinaemia. Rheumatology (Oxford) 43:532-533
23. Koukoulaki M, Abeygunasekara SC, Smith KG et al (2005) Remission of refractory hepatitis C-negative cryoglobulinaemic vasculitis after rituximab and infliximab. Nephrol Dial Transplant 20:213-216
24. Bratcher JM, Korelitz BI (2006) Toxicity of infliximab in the course of treatment of Crohn's disease. Expert Opin Drug Saf 5:9-16
25. Sieper J, Van Den Brande J (2005) Diverse effects of infliximab and etanercept on T lymphocytes. Semin Arthritis Rheum 34:23-27
26. Sandborn WJ, Hanauer SB, Katz S et al (2001) Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial. Gastroenterology 121:1088-1094
27. Marotte H, Fontanges E, Bailly F et al (2007) Etanercept treatment for three months is safe in patients with rheumatological manifestations associated with hepatitis C virus. Rheumatology (Oxford) 46:97-99
28. Vauloup C, Krzysiek R, Greangeot-Keros L et al (2006) Effects of tumor necrosis factor antagonist treatment on hepatitis C-related immunological abnormalities. Eur Cytokine Netw 17:290-293
29. Hunter T (2007) Treatment for chronic myelogenous leukemia: The long road to imatinib. J Clin Invest 117:2036-2043
30. Iyoda M, Hudkins KL, Becker-Herman S et al (2009) Imatinib suppresses cryoglobulinemia and secondary membranoproliferative glomerulonephritis. J Am Soc Nephrol 20:68-77
31. Lam QL, Lo CK, Zheng BJ et al (2007) Impaired V(D)J recombination and increased apoptosis among B cell precursors in the bone marrow of c-Abl-deficient mice. Int Immunol 19:267-276
32. Rolink A, Streb M, Nishikawa S et al (1991) The c-kitencoded tyrosine kinase regulates the proliferation of early pre-B cells. Eur J Immunol 21:2609-2612
33. Nehme-Schuster H, Korganow AS, Pasquali JL et al (2005) Rituximab inefficiency during type I cryoglobulinaemia. Rheumatology (Oxford) 44:410-411
34. Gertz MA, Anagnostopoulos A, Anderson K et al (2003) Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second InternationalWorkshoponWaldenstrom's Macroglobulinemia. Semin Oncol 30:121-126
35. Kapoor P, Greipp PT, Morice WG et al (2008) Anti-CD20 monoclonal antibody therapy in multiple myeloma. Br J Haematol 141:135-148
36. Moreau P, Voillat L, Benboukher L et al (2007) Rituximab in CD20 positive multiple myeloma. Leukemia 21:835-836
37. Chu D, Stevens M, Gladstone DE (2007) Severe, refractory, non-malignant type I cryoglobulinemia treated with alemtuzumab. Rheumatol Int 27:1173-1175
38. Gribben JG, Hallek M (2009) Rediscovering alemtuzumab: current and emerging therapeutic roles. Br J Haematol 144:818-831
39. Knight R (2005) IMiDs: A novel class of immunomodulators. Semin Oncol 32:S24-S30
40. Palumbo A, Facon T, Sonneveld P et al (2008) Thalidomide for treatment of multiple myeloma: 10 years later. Blood 111:3968-3977
41. Paravar T, Lee DJ (2008) Thalidomide: mechanisms of action. Int Rev Immunol 27:111-135
42. Sampson A, Callen JP (2006) The cutting edge: thalidomide for type 1 cryoglobulinemic vasculopathy. Arch Dermatol 142:972-974
43. Cem Ar M, Soysal T, Hatemi G et al (2005) Successful management of cryoglobulinemia-induced leukocytoclastic vasculitis with thalidomide in a patient with multiple myeloma. Ann Hematol 84:609-613
44. Witzens M, Moehler T, Neben K et al (2004) Development of leukocytoclastic vasculitis in a patient with multiple myeloma during treatment with thalidomide. Ann Hematol 83:467-470
45. Lin RJ, Curran JJ, Zimmerman TM et al (2010) Lenalidomide for the treatment of cryoglobulinemia and undifferentiated spondyloarthropathy in a patient with multiple myeloma. J Clin Rheumatol 16:90-91
46. Talamo G, Claxton D, Tricot G et al (2008) Response to bortezomib in refractory type I cryoglobulinemia. Am J Hematol 83:883-884
47. Cavo M (2006) Proteasome inhibitor bortezomib for the treatment of multiple myeloma. Leukemia 20:1341-1352
48. Chad D, Pariser K, Bradley WG et al (1982) The pathogenesis of cryoglobulinemic neuropathy. Neurology 32:725-729
49. Zaltron S, Puoti M, Liberini P et al (1998) High prevalence of peripheral neuropathy in hepatitis C virus infected patients with symptomatic and asymptomatic cryoglobulinaemia. Ital J Gastroenterol Hepatol 30:391-395
50. Roccatello D, Fornasieri A, Giachino O et al (2007) Multicenter study on hepatitis C virus-related cryoglobulinemic glomerulonephritis. Am J Kidney Dis 49:69-82